Dr. Deepak M. Sahasrabudhe, MD

Dr. Sahasrabudhe practices at Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center.

Dr. Sahasrabudhe's NPI, 1750301263, was assigned on July 20, 2006. Dr. Sahasrabudhe graduated from Topiwala National Medical College in 1973. Dr. Sahasrabudhe holds New York license 135467.

Dr. Sahasrabudhe's primary practice is Strong Memorial Hospital, at 601 Elmwood Ave, Rochester, NY 14642 in Monroe County. The practice phone is (585) 275-2121.

Dr. Sahasrabudhe's primary practice is Strong Memorial Hospital in Rochester, New York, part of University of Rochester Medical Center. Dr. Sahasrabudhe is also affiliated with Highland Hospital. The medical group on file is University of Rochester Medical Faculty Group (URMFG). Dmand AI also links Dr. Sahasrabudhe to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sahasrabudhe practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Sahasrabudhe's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Sahasrabudhe is licensed in New York.

CMS data shows 334 Medicare services from Dr. Sahasrabudhe across 4 procedure codes in 2024, for 131 Medicare patients. Medicare paid $24,747 for them.

CMS counts 131 Medicare patients who saw Dr. Sahasrabudhe in 2024. The largest group is 75 to 84, with 54 patients. 70% of them have high blood pressure, and 63% have cancer. 17% are also on Medicaid. Their average risk score is 2.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sahasrabudhe's median patient age at 73, with 23% women.

In 2024, Dr. Sahasrabudhe wrote 490 Medicare Part D claims for 124 patients. 67% of them were for generic drugs. CMS names the drug for 376 of them, across 11 drugs with 11 or more claims each, at $1,502,391 in total drug cost. In 2023, CMS named 333 claims across 11 drugs.

Dr. Sahasrabudhe accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sahasrabudhe as offering telehealth.

Dmand AI links 28 papers to Dr. Sahasrabudhe, published from 2011 to 2024. 2016 was the busiest year, with 5. The most frequent topics are Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols and Cisplatin. Dr. Sahasrabudhe has published most often in J Clin Oncol. Dr. Sahasrabudhe's most frequent co-authors are Chunkit Fung, MD, Elizabeth A. Guancial, MD and Manish Kohli, MD.

Dmand AI links Dr. Sahasrabudhe to 1 clinical trial. Conditions studied include Diabetes Mellitus, Insulin-Dependent, 12 and Neoplasm Metastasis.

CMS Open Payments shows 32 general payments to Dr. Sahasrabudhe from 11 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 49% of the total. EMD Serono, Inc. paid the most, $17,384.

Dr. Sahasrabudhe graduated from Topiwala National Medical College in 1973.